



Company Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Boulder, Colorado, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced

Aug 26 2025, 8:30 AM EDT

Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains

Aug 13 2025, 4:01 PM EDT

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results

Aug 7 2025, 4:15 PM EDT

Stock Overview

Symbol	SNOA
Exchange	Nasdaq
Market Cap	7.49m
Last Price	\$4.56
52-Week	\$1.75 - \$6.9199

08/28/2025 08:00 PM EDT

Investor Relations

T: 470-938-1011
ir@sonomapharma.com

Management Team

Amy Trombly

Chief Executive Officer

Bruce Thornton

Chief Operating Officer

Jerry Dvonch

Chief Financial Officer

Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court
Suite 150
Boulder, CO 80301

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.